Suppr超能文献

心力衰竭的药物治疗:给结构/介入心脏病专家的综述

Heart Failure Medical Therapy: A Review for Structural/Interventional Cardiologists.

作者信息

Pipilas Alexandra, Martyn Trejeeve, Lindenfeld JoAnn

机构信息

Department of Cardiovascular Medicine, Boston University, Boston, Massachusetts, USA.

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.

出版信息

Struct Heart. 2022 Oct 22;6(6):100082. doi: 10.1016/j.shj.2022.100082. eCollection 2022 Nov.

Abstract

Medical therapy for heart failure (HF) has expanded rapidly in the last decade contributing to improved morbidity and mortality for patients living with HF. The indicated treatments have been traditionally stratified based on left ventricular ejection fraction. The optimization of HF medical therapy is important for interventional and structural cardiologists as HF remains among the most common causes of periprocedural hospitalization and death. Additionally, optimization of medical therapy for HF prior to the utilization of device-based therapies as well as enrollment in clinical trials is crucial. This review will serve to highlight medical therapy indicated across the left ventricular ejection fraction strata.

摘要

在过去十年中,心力衰竭(HF)的药物治疗迅速发展,有助于改善HF患者的发病率和死亡率。传统上,已根据左心室射血分数对指定治疗进行分层。HF药物治疗的优化对于介入心脏病学家和心脏结构病学家而言非常重要,因为HF仍然是围手术期住院和死亡的最常见原因之一。此外,在使用基于器械的治疗以及参加临床试验之前,优化HF药物治疗至关重要。本综述将着重介绍适用于不同左心室射血分数分层的药物治疗。

相似文献

1
Heart Failure Medical Therapy: A Review for Structural/Interventional Cardiologists.
Struct Heart. 2022 Oct 22;6(6):100082. doi: 10.1016/j.shj.2022.100082. eCollection 2022 Nov.
5
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Cochrane Database Syst Rev. 2018 Jun 28;6(6):CD012721. doi: 10.1002/14651858.CD012721.pub2.
6
Markers of Iron Metabolism and Outcomes in Patients with Heart Failure: A Systematic Review.
Int J Mol Sci. 2023 Mar 15;24(6):5645. doi: 10.3390/ijms24065645.
7
Focusing Heart Failure Research on Myocardial Fibrosis to Prioritize Translation.
J Card Fail. 2020 Oct;26(10):876-884. doi: 10.1016/j.cardfail.2020.05.009. Epub 2020 May 21.
9
Exercise-based rehabilitation for heart failure.
Cochrane Database Syst Rev. 2014 Apr 27;2014(4):CD003331. doi: 10.1002/14651858.CD003331.pub4.

引用本文的文献

1
Impact of Heart Failure Team on Inpatient Rapid Sequencing of Heart Failure Therapy.
J Cardiovasc Dev Dis. 2025 Jan 28;12(2):50. doi: 10.3390/jcdd12020050.
2
Cardiometabolic Index is associated with heart failure: a cross-sectional study based on NHANES.
Front Med (Lausanne). 2024 Dec 9;11:1507100. doi: 10.3389/fmed.2024.1507100. eCollection 2024.
3
Medication and Outcome in Older Heart Failure Patients: Results from a Prospective Cohort Study.
Pharmaceuticals (Basel). 2024 May 30;17(6):711. doi: 10.3390/ph17060711.

本文引用的文献

1
2
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
Nat Med. 2022 Mar;28(3):568-574. doi: 10.1038/s41591-021-01659-1. Epub 2022 Feb 28.
5
Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction.
J Am Coll Cardiol. 2021 Nov 23;78(21):2042-2056. doi: 10.1016/j.jacc.2021.08.073.
6
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
N Engl J Med. 2021 Nov 11;385(20):1845-1855. doi: 10.1056/NEJMoa2104508.
8
Drug Layering in Heart Failure: Phenotype-Guided Initiation.
JACC Heart Fail. 2021 Nov;9(11):775-783. doi: 10.1016/j.jchf.2021.06.011. Epub 2021 Oct 6.
9
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.
Circulation. 2021 Oct 19;144(16):1284-1294. doi: 10.1161/CIRCULATIONAHA.121.056824. Epub 2021 Aug 29.
10
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验